Lifecore Biomedical's Q3 earnings missed estimates significantly, with an EPS of $-0.22 compared to the expected $-0.13. Additionally, revenue was down $25.47 million from the same period last year. This negative financial performance is likely to have a negative impact on the stock price in the short term.